Osteoprotective https://greenmedinfo.com/category/keywords/Osteoprotective en Beta-caryophyllene may be used as a therapeutic agent for the prevention and treatment of osteoporosis. https://greenmedinfo.com/article/beta-caryophyllene-may-be-used-therapeutic-agent-prevention-and-treatment-oste n/a PMID:  Exp Ther Med. 2016 Dec ;12(6):3602-3606. Epub 2016 Oct 18. PMID: 28105093 Abstract Title:  β-Caryophyllene promotes osteoblastic mineralization, and suppresses osteoclastogenesis and adipogenesis in mouse bone marrow cultures in vitro. Abstract:  Osteoporosis is induced by the reduction in bone mass through decreased osteoblastic osteogenesis and increased osteoclastic bone resorption, and it is associated with obesity and diabetes. Osteoblasts and adipocytes are derived from bone marrow mesenchymal stem cells. The prevention of osteoporosis is an important public health concern in aging populations.β-caryophyllene, a component of various essential oils, is a selective agonist of the cannabinoid receptor type 2 and exerts cannabimimetic anti-inflammatory effects in animals. The present study aimed to identify the effect of β-caryophyllene on adipogenesis, osteoblastic mineralization and osteoclastogenesis in mouse bone marrow cell cultures in vitro. Bone marrow cells obtained from mouse femoral tissues were cultured in the presence of β-caryophyllene (0.1-100 µM) in vitro. The results revealed that β-caryophyllene stimulated osteoblastic mineralization, and suppressed adipogenesis and osteoclastogenesis. Thus, β-caryophyllene may be used as a therapeutic agent for the prevention and treatment of osteoporosis. https://greenmedinfo.com/article/beta-caryophyllene-may-be-used-therapeutic-agent-prevention-and-treatment-oste#comments Beta-Caryophyllene Osteoporosis Osteoprotective Beta-Caryophyllene Osteoporosis Osteoprotective Animal Study Tue, 16 Jan 2018 02:09:02 +0000 greenmedinfo 158456 at https://greenmedinfo.com Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis. https://greenmedinfo.com/article/carnosic-acid-attenuates-rankl-induced-oxidative-stress-and-osteoclastogenesis n/a PMID:  J Mol Med (Berl). 2017 Oct ;95(10):1065-1076. Epub 2017 Jul 4. PMID: 28674855 Abstract Title:  Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling. Abstract:  : Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor, which plays an important role in the cellular defense against oxidative stress by induction of anti-oxidant and cytoprotective enzymes. In the current study, we sought to investigate the osteoprotective effect of carnosic acid (CA), a phenolic (catecholic) diterpene. It is widely identified for its electrophilic nature under oxidative stress conditions and thus anticipated to counter osteoporosis by facilitation of Nrf2 signalling. Osteoclast differentiation was induced by incubation of RAW 264.7 (mouse macrophage) cells and mouse bone marrow macrophages (BMMs) in the presence of receptor activator of NF-κB ligand (RANKL) (100 ng/ml). After treatment, osteoclastogenesis was assessed using tartrate-resistant acid phosphatase (TRAP) assay. We observed that 6 h pretreatment with CA (1.25, 2.5, 5 μM) decreased RANKL-induced osteoclast formation and abolished RANKL-induced ROS generation by activating Nrf2 and its transcriptional targets. Further, CA also inhibited RANKL-induced activation of NF-κB and MAPK signalling. RANKL-induced mRNA expression of osteoclast related genes and transcription factors was also diminished by CA. In vivo osteolysis was developed in C57BL/6 male mice using lipopolysaccharide (LPS). Consistent with in vitro results, in vivo μ-CT analysis of femurs showed that bone mineral density (BMD), bone mineral content (BMC), and bone architecture parameters such as trabecular thickness (Tb.Th) and trabecular space (Tb.Sp) were positively modulated by CA in LPS-injected mice. The results obtained in this study support that CA inhibits RANKL-induced osteoclastogenesis by maintaining redox homeostasis through modulation of Nrf2 and NF-κB pathways. KEY MESSAGES: Carnosic acid (CA) inhibits RANKL-induced osteoclastogenesis. CA inhibits RANKL-induced oxidative stress by upregulating Nrf2 transcriptional targets. CA attenuates RANKL-induced NF-κB and MAPK signalling activation. CA decreases NFATc1 and c-Fos expression. In vivo μ-CT analysis reveals that CA prevents bone loss in LPS-injected mice. https://greenmedinfo.com/article/carnosic-acid-attenuates-rankl-induced-oxidative-stress-and-osteoclastogenesis#comments Bone Diseases Carnosic Acid Anti-Inflammatory Agents Antioxidants NF-kappaB Inhibitor Osteoprotective Anti-Inflammatory Agents Antioxidants Bone Diseases Carnosic Acid NF-kappaB Inhibitor Osteoprotective Animal Study In Vitro Study Fri, 25 May 2018 01:47:26 +0000 greenmedinfo 164771 at https://greenmedinfo.com Greater yogurt consumption is associated with increased bone mineral density and physical function in older adults. https://greenmedinfo.com/article/greater-yogurt-consumption-associated-increased-bone-mineral-density-and-physi n/a PMID:  Osteoporos Int. 2017 May 1. Epub 2017 May 1. PMID: 28462469 Abstract Title:  Greater yogurt consumption is associated with increased bone mineral density and physical function in older adults. Abstract:  : In this cohort of community dwelling older adults (>60 years), we observed significant positive associations between the frequencies of yogurt intake with measures of bone density, bone biomarkers, and indicators of physical function. Improving yogurt intakes could be a valuable health strategy for maintaining bone health in older adults. INTRODUCTION: The associations of yogurt intakes with bone health and frailty in older adults are not well documented. The aim was to investigate the association of yogurt intakes with bone mineral density (BMD), bone biomarkers, and physical function in 4310 Irish adults from the Trinity, Ulster, Department of Agriculture aging cohort study (TUDA). METHODS: Bone measures included total hip, femoral neck, and vertebral BMD with bone biochemical markers. Physical function measures included Timed Up and Go (TUG), Instrumental Activities of Daily Living Scale, and Physical Self-Maintenance Scale. RESULTS: Total hip and femoral neck BMD in females were 3.1-3.9% higher among those with the highest yogurt intakes (n = 970) compared to the lowest (n = 1109; P < 0.05) as were the TUG scores (-6.7%; P = 0.013). In males, tartrate-resistant acid phosphatase (TRAP 5b) concentrations were significantly lower in those with the highest yogurt intakes (-9.5%; P < 0.0001). In females, yogurt intake was a significant positive predictor of BMD at all regions. Each unit increase in yogurt intake in females was associated with a 31% lower risk of osteopenia (OR 0.69; 95% CI 0.49-0.96; P = 0.032) and a 39% lower risk of osteoporosis (OR 0.61; 95% CI 0.42-0.89;P = 0.012) and in males, a 52% lower risk of osteoporosis (OR 0.48; 95% CI 0.24-0.96; P = 0.038). CONCLUSION: In this cohort, higher yogurt intake was associated with increased BMD and physical function scores. These results suggest that improving yogurt intakes could be a valuable public health strategy for maintaining bone health in older adults. https://greenmedinfo.com/article/greater-yogurt-consumption-associated-increased-bone-mineral-density-and-physi#comments Aging Bone Diseases Yoghurt Osteoprotective Aging Bone Diseases Osteoprotective Yoghurt Human Study Fri, 05 May 2017 16:49:50 +0000 greenmedinfo 147301 at https://greenmedinfo.com This study provides a potential treatment candidate for glucocorticoid-induced osteoporosis. https://greenmedinfo.com/article/study-provides-potential-treatment-candidate-glucocorticoid-induced-osteoporos n/a PMID:  Chem Biol Interact. 2016 Aug 25 ;256:188-97. Epub 2016 Jul 5. PMID: 27387537 Abstract Title:  Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway. Abstract:  Glucocorticoid-induced osteoporosis (GIOP) is the primary cause of secondary osteoporosis and the existing therapeutic strategies are limited. The aim of this study is to evaluate the effects of ginsenosides (GS) Rg3 on dexamethasone (DEX)-induced osteoporosis in vivo and in vitro. GIOP rat was established by DEX injection for 5 weeks and treated by GS Rg3 10 or 20 mg/kg. Body weight and bone mineral density (BMD) of rats were measured at the beginning and the end of the experiment. Histological changes of femurs were observed using HE staining. The in vitro model was established on primary osteoblasts induced by DEX. CCK-8 assay was used to test the cell viability. Bone metabolism markers in serum or primary osteoblasts were detected using biochemical kits. Real time PCR and western blot were used to measure nuclear factor-kappa B ligand (RANKL),osteoprotegerin (OPG), bone morphogenic protein-2 (BMP-2), BMP receptor 1A (BMPR1A) and Runx2 expression. The results demonstrated that GS Rg3 prevented DEX-induced body weight and BMD reduction, enhanced secretion of bone formation markers and decreased bone resorption markers. In addition, GS Rg3was found to prevent the suppression of BMP-2/BMPR1A/Runx2 signals induced by DEX both in GIOP rats and primary osteoblasts. Inhibition of BMP-2 by noggin completely blocked the bone-alkaline phosphatase-secretion-promoted effect of GS Rg3 in vitro. These data suggest that GS Rg3 attenuates GIOP through regulating BMP-2 signaling pathway. This study provides a potential drug candidate for GIOP therapy. https://greenmedinfo.com/article/study-provides-potential-treatment-candidate-glucocorticoid-induced-osteoporos#comments Ginsenosides Osteoporosis Dexamethasone Osteoprotective Dexamethasone Ginsenosides glucocorticoid Osteoporosis Osteoprotective Animal Study In Vitro Study Wed, 28 Dec 2016 00:17:14 +0000 greenmedinfo 141077 at https://greenmedinfo.com Using Pueraria mirifica and miroestrol as alternative hormone replacement therapy of E2 might be beneficial. https://greenmedinfo.com/article/using-pueraria-mirifica-and-miroestrol-alternative-hormone-replacement-therapy n/a PMID:  Fitoterapia. 2012 Dec ;83(8):1687-92. Epub 2012 Oct 4. PMID: 23041523 Abstract Title:  Impact of Pueraria candollei var. mirifica and its potent phytoestrogen miroestrol on expression of bone-specific genes in ovariectomized mice. Abstract:  Miroestrol (MR) is a highly active phytoestrogen isolated from tuberous root of Pueraria candollei var. mirifica (PM). Modulatory effects of PM and MR on osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) mRNAs which are bone-specific genes were investigated in ovariectomized female ICR mice. After ovariectomy, expression of OPG mRNA was suppressed but that of RANKL was induced. Estradiol benzoate (E2) recovered OPG expression to the level comparable to the sham while that of RANKL was suppressed in ovariectomized mice. PM crude extract (PME) significantly down-regulated the expression of RANKL mRNA with no change in the OPG level whereas MR elevated the expression of OPG mRNA with lowering level of RANKL mRNA, resulting in the increased OPG/RANKL ratio, and consequently lead to lowering progression of osteoporosis at molecular level. These findings revealed potential of PME and MR on bone loss prevention via increasing the ratio of OPG to RANKL (osteoformation/osteoresorption) in liver of ovariectomized mice. Therefore, using PME and MR as alternative hormone replacement therapy of E2 might be beneficial recommended due to advantageous on regulation of osteoporosis related genes. https://greenmedinfo.com/article/using-pueraria-mirifica-and-miroestrol-alternative-hormone-replacement-therapy#comments Osteoporosis Pueraria mirifica Osteoprotective Gene Expression Regulation Osteoporosis Osteoprotective Ovariectomy-Induced Changes Pueraria mirifica Animal Study Wed, 16 May 2018 21:29:38 +0000 greenmedinfo 164332 at https://greenmedinfo.com